Omeros (OMER) Stock Analysis: AI Score & Alternative Data
OMER alt-data: job postings climbing, web traffic lagging
Is Omeros a buy right now? The alternative data says hold. This OMER stock analysis is built on the 25+ alternative data signals AltIndex tracks on Omeros every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 49/100: a Hold. The stock trades at $16.20 with a $1B market cap.
The bullish side of the 90-day ledger: job postings up 350.0% to 18 open roles. The drag: web traffic down 44.2% to 4K monthly visits, and just 59% of employees report a positive business outlook. That tension is what keeps the score mid-range.
OMER’s broader alt-data profile also covers headcount (221 employees, according to LinkedIn), and sentiment (100/100). Every signal links to its own page with full history, the OMER technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on OMER is just below.
Omeros AI Stock Analysis
Omeros Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for inflammation, coagulopathies, and disorders of the central nervous system. The company's pipeline includes both clinical and preclinical programs.
Analysis generated October 1, 2026.
Recent Omeros Stock Alerts
|
Omeros | October 16 Price is down by -6.4% in the last 24h. |
|
Omeros | September 26 Insider Alert: Borges David J. is selling shares |
|
Omeros | September 22 Price is up by 6.4% in the last 24h. |
|
Omeros | August 30 Insider Alert: HANISH ARNOLD C is selling shares |
Omeros Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 44.2% | |
| Job Posts | 18 | 350.0% | |
| LinkedIn Employees | 221 | 1.3% | |
| Employee Recommend | 61 | 0% | |
| Business Outlook | 59 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | 100.0% | |
| X Mentions | 49 | 4,800.0% | |
| Stocktwits Mentions | 187 | 94.8% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 12K | 2.9% |
About Omeros (OMER)
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
| Price | $16.20 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $1B |
| Year Range | $6 – $21 |
| Dividend Yield | 0% |
| PE Ratio | 13.3 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Omeros News
View more → |
Inside the bitter father-son feud that unravelled the Omeros Bros seafood dynasty - as the tax office winds up the iconic Gold Coast eateryOctober 1 - Dailymail.com |
 |
Why Omeros Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving PremarketAugust 13 - Biztoc.com |
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERJuly 28 - GlobeNewswire |
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMERJuly 21 - GlobeNewswire |
|
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% ReturnJuly 15 - Yahoo Entertainment |
|
See Omeros’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for OMER, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEOmeros Earnings & Financial Performance
View all earnings →Omeros Insider Trading Activity
View all →| Borges David J. filed to sell 0 shares at $0.0. Sep 23 '26 |
| Cancelmo Peter B filed to sell 200 shares at $0.0. Aug 31 '26 |
| HANISH ARNOLD C filed to sell 0 shares at $0.0. Aug 27 '26 |
| Borges David J. filed to sell 0 shares at $0.0. Aug 24 '26 |
| Borges David J. filed to sell 0 shares at $0.0. Aug 21 '26 |
Omeros Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Omeros
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Bicara TherapeuticsBCAX |
$16.78 4.8% | $1B | 45 |
 |
LB PharmaceuticalsLBRX |
$36.74 0.1% | $1B | 47 |
 |
Taysha Gene TherapiesTSHA |
$3.62 3.0% | $1B | 52 |
 |
Alpha Tau MedicalDRTS |
$12.29 6.6% | $1B | 41 |
 |
Amphastar PAMPH |
$25.87 2.1% | $1B | 43 |
Explore Omeros Data
Frequently Asked Questions: Omeros (OMER)
Omeros has an AltIndex AI Score of 49/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
49/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Omeros (OMER) stock is $16.20 with a market cap of $1B.
As of today, Omeros’s PE (Price to Earnings) ratio is 13.3.
View the latest Omeros insider transactions to see recent buying and selling activity by company executives and directors.
Check the Omeros congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The OMER stock price chart above shows Omeros’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Omeros technical analysis for RSI, moving averages, and more.
See the stocks similar to Omeros section on this page for companies in the same industry ranked by market cap and AI Score.
